Anacor Pharmaceuticals Announces Closing of $23 Million Public Offering of Common Stock, Including Full Exercise of

  Anacor Pharmaceuticals Announces Closing of $23 Million Public Offering of
  Common Stock, Including Full Exercise of Underwriters’ Over-Allotment Option

Business Wire

PALO ALTO, Calif. -- May 01, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the completion of its
underwritten public offering of 3,129,890 shares of common stock. In addition,
Anacor announced that the underwriters of this offering exercised their
over-allotment option in full and purchased an additional 469,483 shares of
common stock. Total gross proceeds from this offering are $23.0 million before
deducting the underwriting discount and other offering expenses payable by
Anacor. All of the shares in the offering were sold by Anacor.

Cowen and Company, LLC acted as the sole book-running manager for the offering
with Canaccord Genuity Inc. and Wedbush Securities Inc. acting as co-managers.

The offering was made pursuant to an effective shelf registration statement
previously filed with the Securities and Exchange Commission (SEC). A final
prospectus supplement and accompanying prospectus describing the terms of the
offering was filed with the SEC.

Copies of the final prospectus supplement and accompanying prospectus relating
to the offering may be obtained from Cowen and Company, LLC (c/o Broadridge
Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn:
Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140). The final
prospectus supplement and accompanying prospectus also is available on the
SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell, or the solicitation
of an offer to buy, any of the securities, nor shall there be any sale of
these securities, in any state in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws
of any such state.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
dsheel@anacor.com
 
Press spacebar to pause and continue. Press esc to stop.